Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear

Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug reduces cardiovascular risk.